Some studies reported that responses to PD‐1/PD‐L1 blockade immunotherapies were observed in patients with PD‐L1 expression in tumor‐infiltrating immune cells.19 In addition, Kiyasu et al18 showed a close association between PD‐L1 expression in microenvironmental immune cells and EBV+ tumor cells, consistent with our results. This evidence concerns the gene PDCD1 and neoplasm.